Please assess the completion status of the following clinical trial:

Trial Title: Myfortic Versus Azathioprine in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged 18 years and over~* Patients meeting the diagnostic criteria for SLE (Appendix 2), according to ACR guidelines (including screening for anti-dsDNA (antibody to native DNA in abnormal titer))~* SLEDAI \> 6~* Patients treated with maintenance therapy including azathioprine.~* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained~Exclusion Criteria:~* Creatinine clearance of \< 20ml/min~* Patients with any clinically significant infection~* Patients with known hypersensitivity to myfortic ® or to drugs with similar chemical structures~* Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin~* Patients with SLE active CNS manifestations or a past history of SLE CNS complications (e.g. psychosis, grand mal seizures)~* Patients who have received prior therapy with mycophenolic acids (MPAs) (e.g. MMF)~* Patients who have received an investigational drug within four weeks prior to study entry~* Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).